ResMed Inc (RMD)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE
Market Cap: $33.69B
Last updated: Nov 17, 2026 at 11:06 AM ET
ResMed Inc (RMD) Financials: Revenue, Profit and Cash Flow
ResMed reported revenue of $5.65B for the fiscal year ended Jun 30, 2026, up 9.9% from the year before. That year, net income was $1.52B with a net margin of 26.9%, operating cash flow was $1.81B and free cash flow was $1.65B. The quarter ended Sep 30, 2026 had revenue of $1.41B and net income of $418.41M.
Revenue and Margins
The operating margin was 33.4% in the fiscal year ended Jun 2026, the highest of the 10 years shown. Over the 9 years to Jun 2026, revenue grew from $2.07B, a compound annual rate of 11.8%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Jun 2026 | $5.65B | +9.9% | 61.1% | 33.4% | 26.9% |
| Jun 2025 | $5.15B | +9.8% | 59.4% | 32.7% | 27.2% |
| Jun 2024 | $4.69B | +10.9% | 56.7% | 28.2% | 21.8% |
| Jun 2023 | $4.22B | +18.0% | 55.8% | 26.8% | 21.3% |
| Jun 2022 | $3.58B | +11.9% | 56.6% | 28.0% | 21.8% |
| Jun 2021 | $3.20B | +8.1% | 57.5% | 28.3% | 14.8% |
| Jun 2020 | $2.96B | +13.4% | 58.1% | 27.4% | 21.0% |
| Jun 2019 | $2.61B | +11.4% | 57.3% | 22.2% | 15.5% |
| Jun 2018 | $2.34B | +13.2% | 57.0% | 23.2% | 13.5% |
| Jun 2017 | $2.07B | N/A | 58.1% | 20.6% | 16.6% |
Income Statement
In the fiscal year ended Jun 2026, net income rose 8.6% from the year before. In the quarter ended Sep 2026, net income rose 20.0% from the same quarter a year earlier.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.65B | $5.15B | $4.69B | $4.22B | $3.58B | $3.20B | $2.96B | $2.61B | $2.34B | $2.07B |
| Cost of revenue | $2.20B | $2.09B | $2.03B | $1.87B | $1.55B | $1.36B | $1.24B | $1.11B | $1.01B | $864.99M |
| Gross profit | $3.45B | $3.05B | $2.66B | $2.36B | $2.02B | $1.84B | $1.72B | $1.49B | $1.33B | $1.20B |
| Research and development | $378.29M | $331.28M | $307.52M | $287.64M | $253.57M | $225.28M | $201.95M | $180.65M | $155.15M | $144.47M |
| Operating income | $1.89B | $1.69B | $1.32B | $1.13B | $1.00B | $903.68M | $809.66M | $579.26M | $541.83M | $425.80M |
| Net income | $1.52B | $1.40B | $1.02B | $897.56M | $779.44M | $474.50M | $621.67M | $404.59M | $315.59M | $342.28M |
| EBITDA | $2.11B | $1.91B | $1.53B | $1.35B | $1.19B | $1.11B | $978.88M | $719.33M | $653.25M | $542.05M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.41B | $1.46B | $1.43B | $1.42B | $1.34B | $1.35B | $1.29B | $1.28B | $1.22B | $1.22B | $1.20B | $1.16B |
| Gross profit | $870.57M | $861.22M | $890.98M | $878.72M | $817.66M | $820.07M | $766.41M | $751.27M | $717.22M | $715.53M | $692.78M | $646.93M |
| Operating income | $452.98M | $448.71M | $499.81M | $491.66M | $446.54M | $454.54M | $426.27M | $417.24M | $387.31M | $381.22M | $374.58M | $275.09M |
| Net income | $418.41M | $383.43M | $398.73M | $392.59M | $348.54M | $379.70M | $365.04M | $344.62M | $311.36M | $292.24M | $300.49M | $208.80M |
Balance Sheet
As of Jun 2026, cash and equivalents exceeded total debt of $659.37M by $809.87M.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $8.97B | $8.17B | $6.87B | $6.75B | $5.10B | $4.73B | $4.59B | $4.11B | $3.06B | $3.47B |
| Current assets | $4.32B | $3.51B | $2.36B | $2.37B | $1.93B | $1.57B | $1.52B | $1.15B | $1.07B | $1.64B |
| Cash and equivalents | $1.47B | $1.21B | $238.36M | $227.89M | $273.71M | $295.28M | $463.16M | $147.13M | $188.70M | $821.93M |
| Total liabilities | $2.38B | $2.21B | $2.01B | $2.62B | $1.74B | $1.84B | $2.09B | $2.04B | $1.00B | $1.51B |
| Short-term debt | $259.95M | $9.90M | $9.90M | $9.90M | $9.92M | $12.00M | $11.99M | $11.99M | $11.47M | $214.99M |
| Long-term debt | $399.42M | $658.39M | $697.31M | $1.43B | $765.33M | $643.35M | $1.16B | $1.26B | $269.99M | $1.08B |
| Shareholder equity | $6.59B | $5.97B | $4.86B | $4.13B | $3.36B | $2.89B | $2.50B | $2.07B | $2.06B | $1.96B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $8.21B | $8.97B | $8.78B | $8.50B | $8.31B | $8.17B | $7.57B | $7.14B | $7.22B | $6.87B | $6.81B | $6.91B |
| Total liabilities | $2.26B | $2.38B | $2.29B | $2.18B | $2.19B | $2.21B | $2.02B | $1.89B | $2.03B | $2.01B | $2.18B | $2.42B |
| Cash and equivalents | $1.01B | $1.47B | $1.66B | $1.42B | $1.38B | $1.21B | $932.71M | $521.94M | $426.36M | $238.36M | $237.91M | $210.25M |
| Shareholder equity | $5.95B | $6.59B | $6.49B | $6.32B | $6.12B | $5.97B | $5.55B | $5.25B | $5.20B | $4.86B | $4.63B | $4.48B |
Cash Flow
In the fiscal year ended Jun 2026, free cash flow was 91.2% of operating cash flow. Dividends and share repurchases together came to 63.6% of it.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.81B | $1.75B | $1.40B | $693.30M | $351.15M | $736.72M | $802.25M | $459.05M | $505.03M | $414.05M |
| Capital expenditures | $156.28M | $89.86M | $99.46M | $119.67M | $134.84M | $102.71M | $95.33M | $68.71M | $62.58M | $62.22M |
| Free cash flow | $1.65B | $1.66B | $1.30B | $573.63M | $216.31M | $634.01M | $706.92M | $390.34M | $442.44M | $351.83M |
| Dividends paid | $349.66M | $311.74M | $283.61M | $260.64M | $245.34M | $230.21M | $225.40M | $212.62M | $199.98M | $198.03M |
| Share repurchases | $700.04M | $300.02M | $150.01M | $0 | $0 | N/A | N/A | $22.84M | $53.80M | N/A |
| Investing cash flow | -$545.20M | -$200.04M | -$269.78M | -$1.16B | -$229.92M | -$158.46M | -$179.86M | -$1.08B | -$101.82M | -$81.89M |
| Financing cash flow | -$1.01B | -$606.25M | -$1.12B | $422.87M | -$128.36M | -$764.63M | -$317.29M | $580.64M | -$1.03B | -$262.87M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $422.42M | $454.63M | $554.13M | $339.75M | $457.32M | $538.77M | $578.66M | $308.62M | $325.54M | $440.11M | $402.03M | $272.83M |
| Capital expenditures | $48.74M | $51.13M | $33.65M | $28.54M | $42.97M | $30.59M | $20.80M | $20.64M | $17.84M | $24.88M | $21.19M | $23.35M |
| Free cash flow | $373.68M | $403.50M | $520.48M | $311.21M | $414.36M | $508.18M | $557.87M | $287.98M | $307.70M | $415.23M | $380.84M | $249.48M |
Frequently Asked Questions About RMD
What is ResMed's annual revenue?
ResMed reported revenue of $5.65B for the fiscal year ended Jun 30, 2026.
How fast is ResMed's revenue growing?
Revenue was up 9.9% for the fiscal year ended Jun 30, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 10.2%.
Is ResMed profitable?
Yes. ResMed reported net income of $1.52B for the fiscal year ended Jun 30, 2026, with a net margin of 26.9%.
How much free cash flow does RMD generate?
For the fiscal year ended Jun 30, 2026, operating cash flow of $1.81B minus capital expenditures of $156.28M produced free cash flow of $1.65B.
How much debt does ResMed have?
The balance sheet dated Jun 30, 2026 reported long-term debt of $399.42M, short-term debt of $259.95M and cash and equivalents of $1.47B.
RMD pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors